Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
LIXT logo LIXT
Upturn stock ratingUpturn stock rating
LIXT logo

Lixte Biotechnology Holdings Inc (LIXT)

Upturn stock ratingUpturn stock rating
$3.92
Last Close (24-hour delay)
Profit since last BUY-7.11%
upturn advisory
SELL
SELL since 1 day
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

08/28/2025: LIXT (1-star) is a SELL. SELL since 1 days. Profits (-7.11%). Updated daily EoD!

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Analysis of Past Performance

Type Stock
Historic Profit -70.62%
Avg. Invested days 24
Today’s Advisory SELL
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 1.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 08/28/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 1.97M USD
Price to earnings Ratio -
1Y Target Price -
Price to earnings Ratio -
1Y Target Price -
Volume (30-day avg) -
Beta 0.37
52 Weeks Range 0.64 - 3.00
Updated Date 06/30/2025
52 Weeks Range 0.64 - 3.00
Updated Date 06/30/2025
Dividends yield (FY) -
Basic EPS (TTM) -1.45

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -81.14%
Return on Equity (TTM) -155.14%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 4085448
Price to Sales(TTM) -
Enterprise Value 4085448
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -1.5
Shares Outstanding 2756990
Shares Floating 2527941
Shares Outstanding 2756990
Shares Floating 2527941
Percent Insiders 18.43
Percent Institutions 15.84

ai summary icon Upturn AI SWOT

Lixte Biotechnology Holdings Inc

stock logo

Company Overview

overview logo History and Background

Lixte Biotechnology Holdings Inc. was founded in 2005. It is a biotechnology company focused on developing cancer treatments, particularly through the use of protein phosphatase inhibitors. Key milestones include preclinical and clinical trials of its lead compound, LB-100.

business area logo Core Business Areas

  • Drug Development: Focused on developing and commercializing novel therapies for cancer and other diseases.

leadership logo Leadership and Structure

Dr. John S. Kovach is the CEO of Lixte Biotechnology Holdings Inc. The company operates with a small management team and collaborates with research institutions for drug development.

Top Products and Market Share

overview logo Key Offerings

  • LB-100: LB-100 is Lixte's lead compound, a protein phosphatase 2A (PP2A) inhibitor in clinical development for various cancers. Market share data is not readily available as it is still in clinical trials. Competitors in the PP2A inhibition space are emerging, but LB-100 is among the more advanced clinically. Competitors include companies developing other protein phosphatase inhibitors or therapies targeting similar cancer pathways.

Market Dynamics

industry overview logo Industry Overview

The pharmaceutical industry is highly competitive, with significant investment in research and development. The oncology market is growing due to an aging population and advances in cancer diagnostics and treatment.

Positioning

Lixte is a small biotechnology company focusing on a specific therapeutic approach (PP2A inhibition). Its competitive advantage lies in its proprietary compounds and clinical data, though its size limits its resources compared to larger pharmaceutical companies.

Total Addressable Market (TAM)

The total addressable market for cancer therapies is estimated in the hundreds of billions of dollars globally. Lixte's positioning depends on the success of LB-100 and its ability to capture a share of specific cancer treatment markets.

Upturn SWOT Analysis

Strengths

  • Proprietary compounds
  • Focus on a specific therapeutic target (PP2A inhibition)
  • Early-stage clinical data showing promise
  • Experienced management team

Weaknesses

  • Limited financial resources
  • Dependence on a single lead compound (LB-100)
  • Small company size relative to competitors
  • High risk associated with drug development

Opportunities

  • Partnerships with larger pharmaceutical companies
  • Expansion of LB-100 into additional cancer indications
  • Positive clinical trial results
  • Potential for breakthrough therapy designation

Threats

  • Clinical trial failures
  • Competition from other cancer therapies
  • Regulatory hurdles
  • Funding challenges

Competitors and Market Share

competitor logo Key Competitors

  • MRNA
  • PFE
  • JNJ

Competitive Landscape

Lixte faces significant competition from larger pharmaceutical companies with greater resources. Its advantage lies in its specific therapeutic target and potential for a novel treatment approach. Lixte is disadvantaged due to its smaller size, limited financial resources, and dependence on the success of its lead compound.

Growth Trajectory and Initiatives

Historical Growth: Historical growth has been primarily driven by research and development progress rather than revenue generation.

Future Projections: Future growth depends on the successful development and commercialization of LB-100. Analyst estimates are variable and dependent on clinical trial outcomes.

Recent Initiatives: Recent initiatives include ongoing clinical trials of LB-100 in various cancer types and exploring potential partnerships.

Summary

Lixte Biotechnology is a high-risk, high-reward biotechnology company focused on developing LB-100. Success hinges on positive clinical trial results and securing partnerships. Its small size and limited financial resources pose challenges. It needs to generate positive clinical data and explore partnerships to accelerate development and commercialization.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • SEC Filings
  • Company Website
  • Analyst Reports (where available)

Disclaimers:

This analysis is based on publicly available information and is not financial advice. The biotechnology industry is inherently risky, and investment decisions should be made with caution.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Lixte Biotechnology Holdings Inc

Exchange NASDAQ
Headquaters Pasadena, CA, United States
IPO Launch date 2007-09-21
CEO & Chairman Mr. Geordan G. Pursglove
Sector Healthcare
Industry Biotechnology
Full time employees 2
Full time employees 2

Lixte Biotechnology Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colorectal cancer. The company's LB-100 combined with doxorubicin in advanced soft tissue sarcoma is under Phase 1b portion; and LB-100 combined with dostarlimab that is in phase 1b/2 for ovarian clear cell carcinoma. The company has a clinical trial research agreement with the Netherlands Cancer Institute; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group; and a development collaboration agreement with the Netherlands Cancer Institute. Lixte Biotechnology Holdings, Inc. was founded in 2005 and is based in Pasadena, California.